z-logo
Premium
Transition to noncurative end‐of‐life care in paediatric oncology – a nationwide follow‐up in Sweden
Author(s) -
Jalmsell Li,
Forslund Martin,
Hansson Mats G,
Henter JanInge,
Kreicbergs Ulrika,
Frost BrittMarie
Publication year - 2013
Publication title -
acta paediatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/apa.12242
Subject(s) - medicine , malignancy , pediatrics , medical record , end of life care , retrospective cohort study , relative risk , palliative care , cause of death , confidence interval , disease , nursing
Aim To estimate whether and when children dying from a malignancy are recognized as being beyond cure and to study patterns of care the last weeks of life. Methods A nationwide retrospective medical record review was conducted. Medical records of 95 children (60% of eligible children) who died from a malignancy 2007–2009 in Sweden were studied. Results Eighty‐three children (87%) were treated without curative intent at the time of death. Children with haematological malignancies were less likely to be recognized as being beyond cure than children with brain tumours [relative risks ( RR ) 0.7; 95% confidence interval ( CI ) 0.6–0.9] or solid tumours ( RR 0.8; 0.6–1.0). The transition to noncurative care varied from the last day of life to over four years prior to death (median 60 days). Children with haematological malignancies were treated with a curative intent closer to death and were also given chemotherapy ( RR 5.5; 1.3–22.9), transfusions ( RR 2.0; 1.0–4.0) and antibiotics ( RR 5.3; 1.8–15.5) more frequently than children with brain tumours the last weeks of life. Conclusion The majority of children dying from a malignancy were treated with noncurative intent at the time of death. The timing of a transition in care varied with the diagnoses, being closer to death in children with haematological malignancies.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here